Key Takeaways

  • Delivra Health Brands reported net revenue of $6.887 million for the nine months to 31 March 2026, down 24% year on year, with adjusted EBITDA of negative $1.262 million.
  • The company attributed most of the shortfall to reduced Dream Water shipments from the United States to Middle East distribution partners amid regional conflict, including the closure of the Strait of Hormuz.
  • Between March and July 2026 the company launched Dream Water Kids Sleep Gummies in the United States, signed a five-year licence with Peak Processing for LivRelief Infused topicals, and launched a LivRelief Itch Relief Cream in Canada.

Delivra Health Brands Inc. (TSXV:DHB) began its 2026 financial year describing a business with momentum: annual revenue up 8%, positive adjusted EBITDA for a second consecutive year, and a widening international footprint for its Dream Water sleep range. Nine months later the picture looks materially different. Disruption to shipping in the Middle East removed roughly $1.8 million from year-to-date United States sales, gross margin compressed from 49% to 40%, and the shares changed hands at about ten Canadian cents in late July 2026. Against that backdrop the company has pushed out three product and licensing initiatives in four months.

A Small Canadian Consumer Health Company With Two Brands

Delivra Health Brands is a Vancouver-headquartered consumer packaged goods company operating in the health and wellness category. It was formerly known as Harvest One Cannabis, and today sells through two subsidiary brands: Dream Water, a sleep range comprising liquid shots, gummies and powder packets, and LivRelief, a topical cream range using a proprietary transdermal delivery system. The company employs 27 people and carried a market capitalization of roughly C$3.1 million at the end of July 2026.

An Itch Relief Cream Extends the LivRelief Range

On 2 July 2026, the company announced the launch of a LivRelief Itch Relief Cream in Canada, available to distributors, retailers and e-commerce channels. The company said the formulation combines hydrocortisone with calendula and chamomile, is hypoallergenic and fragrance-free. Management positioned the product against itchiness associated with eczema, psoriasis and dermatitis, and minor irritations.

How Delivra Health Brands Generates Revenue

The business model is asset-light branded consumer goods. Delivra designs and markets products, then sells them through retail and pharmacy chains, distributors and its own direct-to-consumer e-commerce channels, with additional volume routed through international distribution partners across more than 20 countries.

The two channels are currently moving in opposite directions. For the nine months to 31 March 2026, e-commerce sales rose 13% for Dream Water in Canada and 32% for LivRelief. Over the same period, Dream Water Canada retail sales fell 6% and LivRelief retail sales fell 27%. Management has framed direct-to-consumer as a higher-margin channel and said it intends to keep investing there while working to stabilize retail ordering patterns.

Products, Licensing and Route to Market

Two earlier 2026 announcements are relevant. On 19 March 2026 the company said it would launch Dream Water Kids Sleep Gummies in the United States, with 1 mg of melatonin and no artificial colours or flavours. On 22 April 2026, subsidiary LivCorp Inc. entered a five-year licence agreement with Peak Processing Solutions to manufacture, distribute and sell infused LivRelief-branded topicals in Canada, replacing an earlier licensed distribution channel whose wind-down had been a visible drag on reported sales.

Recent Financial and Operational Performance

Fiscal 2025, ended 30 June 2025, was the stronger comparison period: net revenue reached $13.370 million against $12.378 million in fiscal 2024, with gross profit of $6.778 million at a 51% margin and adjusted EBITDA of $643 thousand.

Fiscal 2026 has deteriorated. Third-quarter net revenue dropped about 60% to $1.247 million from $3.095 million, with gross profit of $311 thousand at a 25% margin. For the nine months, net revenue of $6.887 million was 24% below the prior year, adjusted EBITDA was negative $1.262 million and the net loss was $1.530 million.

Management attributed the bulk of the shortfall to a $1.785 million reduction in Dream Water sales from the United States to Middle East distribution partners, citing regional conflict and the closure of the Strait of Hormuz, plus $281 thousand of lower LivRelief Infused activity during the licensing transition. Costs were cut: nine-month expenses excluding non-cash items fell 11% to $4.099 million.

Balance Sheet and Potential Catalysts

Cash stood at $2.64 million at 31 March 2026, down from $3.49 million a year earlier, against total current liabilities of $2.17 million. Shareholders' equity stood at $2.94 million — broadly in line with the company's market capitalization at the time of writing.

Management has said it anticipates shipping and delivery to the Middle East region resuming in the fourth quarter and into fiscal 2027, referencing new order commitments from international partners. That's an expectation, not a completed transaction. Other identified catalysts include the commercial ramp of the Peak-manufactured infused topicals and the first full quarters of contribution from the kids gummies and the itch cream.

Industry Context for Natural Health Products

The categories Delivra Health competes in — sleep support and topical relief — are crowded and increasingly commoditized, with private-label and multinational competitors holding significant shelf presence. In Canada, natural health products are regulated under the Natural Health Products Regulations, a framework requiring valid product and site licences and good manufacturing practice compliance.

Principal Risks

  • Customer and geographic concentration — a single regional distribution disruption erased roughly 60% of quarterly revenue
  • Retail listing losses, with LivRelief retail sales down 27% over nine months
  • Finite working capital, with cash falling roughly $850 thousand over the year to 31 March 2026
  • Execution risk on three simultaneous launches
  • Dependence on a single licensee for infused topicals, plus tariff and input-cost inflation

What to Watch Next

  • Fiscal 2026 full-year results, expected around early October 2026
  • Whether Middle East shipments resumed in the June quarter
  • Whether gross margin recovers from the 25% trough toward historical levels near 50%
  • Whether retail declines stabilize
  • Early sell-through data on the itch cream and kids gummies

Conclusion

Delivra Health Brands is a genuinely small company navigating a shock it didn't create. The e-commerce trend lines and the cost discipline are real, as is a balance sheet that remains solvent with positive working capital. Equally real is a 24% nine-month revenue decline, negative adjusted EBITDA and a share price down about 55% over twelve months. The new products broaden the portfolio, but none has yet appeared meaningfully in reported revenue. The fiscal 2026 annual results, and the fiscal 2027 quarters that follow, will show whether product expansion is enough to offset what was lost.